Abiopharma

🔍 Cuffe Michael S. (Executive)

Company: HCA Healthcare, Inc. (HCA)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Acquired 10,920 shares of Common Stock at $173.12 per share (Direct)
  Date: 2025-09-04 | Code: M | equity_swap_involved: false | shares_owned_after: 42,422.90 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 7,084 shares of Common Stock at $411.59 per share (Direct)
  Date: 2025-09-04 | Code: F | equity_swap_involved: false | shares_owned_after: 35,338.90 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,836 shares of Common Stock at $418.84 per share (Direct)
  Date: 2025-09-08 | Code: S | equity_swap_involved: false | shares_owned_after: 31,502.90 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 10,920 shares of Stock Appreciation Right at $173.12 per share (Derivative)
  Date: 2025-09-04 | Code: M | Expires: 2031-02-03 | equity_swap_involved: false | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.
• F2: Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans.
• F3: The stock appreciation rights vested in four equal annual installments beginning on February 3, 2022.